Engineered T Cells Show Promise Against Deadly Mesothelioma Cancer
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
86 articles in this topic
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Phase II trial tested nivolumab with or without ipilimumab in 164 patients with metastatic sarcoma that couldn't be surgically removed.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.